Detailed Information on Publication Record
2021
Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms
ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ and Miroslav PENKABasic information
Original name
Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms
Authors
ASWAD, Mohamed Hussam (760 Syrian Arab Republic, guarantor, belonging to the institution), Jarmila KISSOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution)
Edition
Neoplasma, Bratislava, Slovenská akademie vied, 2021, 0028-2685
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
Slovakia
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.409
RIV identification code
RIV/00216224:14110/21:00122606
Organization unit
Faculty of Medicine
UT WoS
000729198300012
Keywords in English
Myeloproliferative neoplasm; Thrombosis; Risk factor; JAK2V617F mutation; Smoking
Tags
International impact, Reviewed
Změněno: 17/5/2022 10:49, Mgr. Tereza Miškechová
Abstract
V originále
Thrombosis is the most common complication in BCR-ABL1 negative myeloproliferative neoplasms (MPN) that significantly impacts patients’ mortality. Generally, there is an agreement on risk factors that possibly contribute to the increased risk of thrombosis, including age, history of thrombosis, JAK2V617F mutation, and cardiovascular risk factors. This study retrospectively investigates MPN-related and patient-related variables in relation to the thrombosis occurrence in MPN. Our analyses show that JAK2V617F-mutated patients are at a significantly increased risk of thrombosis within five years before the MPN diagnosis point with a hazard ratio (HR) of 15.49 (P = 0.006). In multivariate analyses, independent risk factors for thrombotic complications during the follow-up are history of thrombosis (HR = 2.23, P = 0.019), age over 60 years at diagnosis (HR = 1.56, P = 0.037), the presence of JAK2V617F mutation (HR = 3.01, P = 0.002), and tobacco smoking (HR = 1.75, P = 0.01). Our results support the multifactorial mechanism of thrombosis in MPN patients, which demands individual and complex management.